Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX)

Ultragenyx announced the EMA validated its MAA for UX111, a gene therapy for MPS IIIA, allowing formal review. This follows prior U.S. approval and may lead to EU market access if approved.

Ultragenyx submitted a Marketing Authorisation Application (MAA) to the EMA for its gene therapy rebisufligene etisparvovec, targeting MPS IIIA (Sanfilippo syndrome Type A). The EMA validated the application, initiating a formal review. The therapy has received PRIME and Orphan Drug Designations. Ultragenyx aims to expand regulatory discussions globally. MPS IIIA is a rare, fatal disorder with limited treatment options.

Ultragenyx Pharmaceutical (RARE) received FDA approval for FAYUVI, a gene therapy for Sanfilippo syndrome Type A. This is the first treatment for this rare disease and includes a Priority Review Voucher. The approval validates Ultragenyx's capabilities and addresses prior regulatory concerns. Analysts forecast earnings of $43.8M by 2029, assuming revenue growth to $1.2B, but risks include high cash burn and potential dilution.

Ultragenyx Pharmaceutical (RARE) shares rose 9% this week after FDA approved Fayuvi, a gene therapy for Sanfilipso syndrome, and raised price targets. The stock rebounded from a 44% drop after its Angelman syndrome trial failed. Analysts see value in its $1.4B market cap and new therapies. RARE plans to sell priority review vouchers for ~$400M.

Ultragenyx (RARE) received FDA approval for Fayuvi, a treatment for Sanfilippo syndrome Type A, causing a 12% stock jump. The company aims for profitability by 2027, with Fayuvi expected to contribute significantly to revenue. Fayuvi is priced at $3.95 million per treatment, with estimated peak sales of $200M-$250M. Hedge funds and short interest activity increased before the approval.

The FDA approved Ultragenyx's gene therapy Fayuvi (rebisufligene etisparvovec) for Sanfilippo syndrome type A. The drug, priced at $3.95M per dose, is the first treatment for this rare pediatric disease. Ultragenyx's stock (RARE) rose over 12% following the approval, which also included another gene therapy, Genglycos, priced at $2.7M.